Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Clinical bottom line
Enteral sildenafil reduced the incidence of rebound pulmonary hypertension in children (GRADE B).
Assisting weaning, sildenafil may facilitate reduced duration of mechanical ventilation and intensive care unit stay (GRADE B).
An 8-week-old infant is receiving inhaled nitric oxide (iNO) for secondary pulmonary hypertension (PHT) in paediatric intensive care unit (PICU). The child is postcongenital diaphragmatic hernia repair and is proving difficult to wean from iNO. Given the problem with rebound PHT, you wonder if treatment with enteral sildenafil will aid discontinuation of iNO.
Structured clinical question
In the child with pulmonary hypertension (population), does treatment with enteral sildenafil (intervention) compared with a slow wean from iNO alone (comparison) prevent rebound PHT and allow for discontinuation of iNO (outcome)?
We performed an online search using PubMed and Medline (1946 to present) in September 2019. The key terms were (pulmonary hypertension) AND (rebound) AND (sildenafil) AND (nitric oxide) AND (child). We limited the search to include articles written in English. We identified three relevant articles, a randomised controlled trial, a prospective and a retrospective …
Twitter @No twitter
Contributors SM and SMcV devised the question. SM searched the literature, critically analysed it and produced the initial draft. AT and TB helped SM edit the article.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.